Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf

Executive Summary

At a time when $10,000-per-month pricing is the norm in oncology, GSK has priced its just-approved BRAF inhibitor Tafinlar at $7,600, on the lower end by today’s standards. Company says it is planning to file the combination of Tafinlar with Mekinist – also just approved by FDA – in a matter of weeks in the U.S.

You may also be interested in...

GSK’s Mekinist/Tafinlar Combo Pushes The Price Bar

GSK’s MEK inhibitor Mekinist and BRAF inhibitor Tafinlar are the first two targeted therapies approved in combination for the treatment of metastatic melanoma. The prices of the separate components are below other comparable oncology launches, but the combination will push the price to over $17,115 for a month of treatment.

GSK Establishes Oncology Consortium With An Eye On Combinations

The company has aligned with six leading cancer centers to study investigational cancer drugs, with the ambition of advancing novel combinations, including both targeted therapies and immunotherapies.

Vical Shifts To Infectious Disease After Allovectin Fails In Melanoma

CEO Vijay Samant defends Vical’s DNA-based technology platform after 20 years of development culminates in Phase III failure. But the platform still shows promise in other therapeutic areas, Vical says as the company absorbs a major blow to stock price.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts